People
Another bluebird bio executive is jumping ship. Chief Medical Officer David Davidson is leaving the company on April 16.
BioSpace recently spoke with Sanjeev Luther, CEO and board member of Rafael Pharmaceuticals, a clinical-late stage metabolic therapeutics company.
German shepherds take down bad guys, dalmatians pull people from fires, beagles sniff out bombs and now llamas fight COVID-19.
Five months after Be Biopharma launched with $52 million in Series A financing, the company tapped bluebird bio veteran Joanne Smith-Farrell as its new chief executive officer.
Aron Knickerbocker, former Chief Executive Officer (CEO) of RayzeBio and Five Prime Therapeutics, has taken the helm of Aulos Bioscience, a relatively new biotech company focused on the development of highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies the treatment of solid tumors.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
It has been one year since COVID-19 was declared a global pandemic. In that time, more than 118 million people have contracted the virus and 2,622,190 people, including 529,267 in the United States, have died as a result.
GlaxoSmithKline failed to hit a key internal profit goal in 2020, due in large part to the impact of the COVID-19 pandemic. As a result, Chief Executive Officer Emma Walmsley took a nearly $2 million hit to her annual compensation.
Doudna, the subject of a new book by Walter Isaacson titled “The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race,” has kept busy.
Despite a historic push for greater diversity and inclusion (D&I), a significant disconnect prevails between good intentions and actual lived experiences.
PRESS RELEASES